当前位置： SCI文献检索 > CANCER CELL期刊下所有文献 > Cell signaling and cancer.

Cell signaling and cancer.

Abstract：

:During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. Many of the proteins currently under investigation as possible targets for cancer therapy are signaling proteins that are components of these pathways. The nature of these signaling pathways and their roles in tumorigenesis were the subject of a recent Beatson International Cancer Conference.

journal_name

Cancer Cell

journal_title

Cancer cell

authors

Martin GS

doi

10.1016/s1535-6108(03)00216-2

keywords:

subject

Has Abstract

pub_date

2003-09-01 00:00:00

pages

167-74

issue

3

eissn

1535-6108

issn

1878-3686

pii

S1535610803002162

journal_volume

4

pub_type

杂志文章,评审

相关文献

CANCER CELL文献大全
  • Her 2 in 1.

    abstract：:In this issue of Cancer Cell, Park et al. demonstrate that anti-erbB2 antibody primes adaptive immunity for increased tumor clearance and suggest that chemotherapy may in fact interfere with this process. ...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2010.07.009

    authors： Smyth MJ,Stagg J

    更新日期：2010-08-09 00:00:00

  • Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases.

    abstract：:Mdmx is a critical negative regulator of the p53 pathway that is stoichiometrically limiting in some tissues. Posttranslational modification and degradation of Mdmx after DNA damage have been proposed to be essential for p53 activation. We tested this model in vivo, where critical stoichiometric relationships are pres...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2009.05.008

    authors： Wang YV,Leblanc M,Wade M,Jochemsen AG,Wahl GM

    更新日期：2009-07-07 00:00:00

  • Haploinsufficiency of SAMD9L, an endosome fusion facilitator, causes myeloid malignancies in mice mimicking human diseases with monosomy 7.

    abstract：:Monosomy 7 and interstitial deletion of 7q (-7/7q-) are well-recognized nonrandom chromosomal abnormalities frequently found among patients with myelodysplastic syndromes (MDSs) and myeloid leukemias. We previously identified candidate myeloid tumor suppressor genes (SAMD9, SAMD9-like = SAMD9L, and Miki) in the 7q21.3...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2013.08.011

    authors： Nagamachi A,Matsui H,Asou H,Ozaki Y,Aki D,Kanai A,Takubo K,Suda T,Nakamura T,Wolff L,Honda H,Inaba T

    更新日期：2013-09-09 00:00:00

  • Protein Kinase Cι and Wnt/β-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma.

    abstract：:We report that mouse LSL-KrasG12D;Trp53fl/fl (KP)-mediated lung adenocarcinoma (LADC) tumorigenesis can proceed through both PKCι-dependent and PKCι-independent pathways. The predominant pathway involves PKCι-dependent transformation of bronchoalveolar stem cells (BASCs). However, KP mice harboring conditional knock o...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2019.07.002

    authors： Yin N,Liu Y,Khoor A,Wang X,Thompson EA,Leitges M,Justilien V,Weems C,Murray NR,Fields AP

    更新日期：2019-08-12 00:00:00

  • Twist1-induced invadopodia formation promotes tumor metastasis.

    abstract：:The Twist1 transcription factor is known to promote tumor metastasis and induce Epithelial-Mesenchymal Transition (EMT). Here, we report that Twist1 is capable of promoting the formation of invadopodia, specialized membrane protrusions for extracellular matrix degradation. Twist1 induces PDGFRα expression, which in tu...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2011.01.036

    authors： Eckert MA,Lwin TM,Chang AT,Kim J,Danis E,Ohno-Machado L,Yang J

    更新日期：2011-03-08 00:00:00

  • MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis.

    abstract：:MYC is an oncogenic driver that regulates transcriptional activation and repression. Surprisingly, mechanisms by which MYC promotes malignant transformation remain unclear. We demonstrate that MYC interacts with the G9a H3K9-methyltransferase complex to control transcriptional repression. Inhibiting G9a hinders MYC ch...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2018.09.001

    authors： Tu WB,Shiah YJ,Lourenco C,Mullen PJ,Dingar D,Redel C,Tamachi A,Ba-Alawi W,Aman A,Al-Awar R,Cescon DW,Haibe-Kains B,Arrowsmith CH,Raught B,Boutros PC,Penn LZ

    更新日期：2018-10-08 00:00:00

  • Opening a new GATAway for treating KRAS-driven lung tumors.

    abstract：:In a recent issue of Cell, Kumar and colleagues uncovered a synthetic lethal interaction between oncogenic KRAS and the transcription factor GATA2 in non-small cell lung carcinoma. Pharmacological inhibition of GATA2-mediated pathways with bortezomib and fasudil results in dramatic tumor inhibition. These observations...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2012.04.032

    authors： Barbacid M

    更新日期：2012-05-15 00:00:00

  • miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis.

    abstract：:To metastasize, a tumor cell must acquire abilities such as the capacity to colonize new tissue and evade immune surveillance. Recent evidence suggests that microRNAs can promote the evolution of malignant behaviors by regulating multiple targets. We performed a microRNA analysis of human melanoma, a highly invasive c...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2011.05.027

    authors： Gaziel-Sovran A,Segura MF,Di Micco R,Collins MK,Hanniford D,Vega-Saenz de Miera E,Rakus JF,Dankert JF,Shang S,Kerbel RS,Bhardwaj N,Shao Y,Darvishian F,Zavadil J,Erlebacher A,Mahal LK,Osman I,Hernando E

    更新日期：2011-07-12 00:00:00

  • Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

    abstract：:Recent structural studies of epidermal growth factor receptor (EGFR) family extracellular regions have identified an unexpected mechanism for ligand-induced receptor dimerization that has important implications for activation and inhibition of these receptors. Here we describe the 2.8 angstroms resolution X-ray crysta...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2005.03.003

    authors： Li S,Schmitz KR,Jeffrey PD,Wiltzius JJ,Kussie P,Ferguson KM

    更新日期：2005-04-01 00:00:00

  • Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency.

    abstract：:Bladder cancer incurs a higher lifetime treatment cost than other cancers due to frequent recurrence of non-invasive disease. Improved prognostic biomarkers and localized therapy are needed for this large patient group. We defined two major genomic subtypes of primary stage Ta tumors. One of these was characterized by...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2017.08.005

    authors： Hurst CD,Alder O,Platt FM,Droop A,Stead LF,Burns JE,Burghel GJ,Jain S,Klimczak LJ,Lindsay H,Roulson JA,Taylor CF,Thygesen H,Cameron AJ,Ridley AJ,Mott HR,Gordenin DA,Knowles MA

    更新日期：2017-11-13 00:00:00

  • IRS-1: auditing the effectiveness of mTOR inhibitors.

    abstract：:Rapamycin analogs that inhibit mTOR signaling have antitumor activity against certain lymphomas, but treatment of solid tumors has been less encouraging despite inhibition of mTOR function. Two recent papers give insight into the potential use of mTOR inhibitors. O'Reilly et al. provide evidence that poor tumor respon...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/j.ccr.2006.02.027

    authors： Easton JB,Kurmasheva RT,Houghton PJ

    更新日期：2006-03-01 00:00:00

  • TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer.

    abstract：:The MAP3-kinase TGF-beta-activated kinase 1 (TAK1) critically modulates innate and adaptive immune responses and connects cytokine stimulation with activation of inflammatory signaling pathways. Here, we report that conditional ablation of TAK1 in liver parenchymal cells (hepatocytes and cholangiocytes) causes hepatoc...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2010.03.021

    authors： Bettermann K,Vucur M,Haybaeck J,Koppe C,Janssen J,Heymann F,Weber A,Weiskirchen R,Liedtke C,Gassler N,Müller M,de Vos R,Wolf MJ,Boege Y,Seleznik GM,Zeller N,Erny D,Fuchs T,Zoller S,Cairo S,Buendia MA,Prinz M,A

    更新日期：2010-05-18 00:00:00

  • A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.

    abstract：:Although signaling from phosphatidylinositol 3-kinase (PI3K) and AKT to mechanistic target of rapamycin (mTOR) is prominently dysregulated in high-grade glial brain tumors, blockade of PI3K or AKT minimally affects downstream mTOR activity in glioma. Allosteric mTOR inhibitors, such as rapamycin, incompletely block mT...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2017.01.014

    authors： Fan Q,Aksoy O,Wong RA,Ilkhanizadeh S,Novotny CJ,Gustafson WC,Truong AY,Cayanan G,Simonds EF,Haas-Kogan D,Phillips JJ,Nicolaides T,Okaniwa M,Shokat KM,Weiss WA

    更新日期：2017-03-13 00:00:00

  • Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically.

    abstract：:Among the cytokines linked to inflammation-associated cancer, interleukin (IL)-6 drives many of the cancer "hallmarks" through downstream activation of the gp130/STAT3 signaling pathway. However, we show that the related cytokine IL-11 has a stronger correlation with elevated STAT3 activation in human gastrointestinal...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2013.06.017

    authors： Putoczki TL,Thiem S,Loving A,Busuttil RA,Wilson NJ,Ziegler PK,Nguyen PM,Preaudet A,Farid R,Edwards KM,Boglev Y,Luwor RB,Jarnicki A,Horst D,Boussioutas A,Heath JK,Sieber OM,Pleines I,Kile BT,Nash A,Greten FR,McKe

    更新日期：2013-08-12 00:00:00

  • NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.

    abstract：:Using sequential gene expression profiling (GEP) samples, we defined a major functional group related to drug resistance that contains chromosomal instability (CIN) genes. One CIN gene in particular, NEK2, was highly correlated with drug resistance, rapid relapse, and poor outcome in multiple cancers. Overexpressing N...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2012.12.001

    authors： Zhou W,Yang Y,Xia J,Wang H,Salama ME,Xiong W,Xu H,Shetty S,Chen T,Zeng Z,Shi L,Zangari M,Miles R,Bearss D,Tricot G,Zhan F

    更新日期：2013-01-14 00:00:00

  • PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia.

    abstract：:PML/RARalpha is of crucial importance in acute promyelocytic leukemia (APL) both pathologically and therapeutically. Using a genome-wide approach, we identified in vivo PML/RARalpha binding sites in a PML/RARalpha-inducible cell model. Of the 2979 targeted regions, >62% contained canonical PU.1 motifs and >84% of thes...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2009.12.045

    authors： Wang K,Wang P,Shi J,Zhu X,He M,Jia X,Yang X,Qiu F,Jin W,Qian M,Fang H,Mi J,Yang X,Xiao H,Minden M,Du Y,Chen Z,Zhang J

    更新日期：2010-02-17 00:00:00

  • A New Role for Lyn in the CLL Microenvironment.

    abstract：:The role of Lyn, both a positive and a negative regulator of B and myeloid cells, in chronic lymphocytic leukemia (CLL) has not been well characterized. In this issue of Cancer Cell, Nguyen et al. demonstrated that Lyn in macrophages rather than in CLL cells is critical for the malignancy. ...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2016.09.018

    authors： Dong S,Byrd JC

    更新日期：2016-10-10 00:00:00

  • CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis.

    abstract：:A large body of evidence indicates that chronic inflammation is one of several key risk factors for cancer initiation, progression, and metastasis. However, the underlying mechanisms responsible for the contribution of inflammation and inflammatory mediators to cancer remain elusive. Here, we present genetic evidence ...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2013.10.009

    authors： Katoh H,Wang D,Daikoku T,Sun H,Dey SK,Dubois RN

    更新日期：2013-11-11 00:00:00

  • GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer.

    abstract：:Androgen deprivation therapy (ADT) for advanced prostate cancer inexorably leads to resistance, and clinically useful biomarkers are lacking. The value of genetically engineered mice for coclinical studies is clearly demonstrated in a recent publication that reveals XAF1, XIAP, and SRD5A1 as novel predictive biomarker...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2013.06.007

    authors： Karantanos T,Thompson TC

    更新日期：2013-07-08 00:00:00

  • Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.

    abstract：:We investigated the transcriptional and epigenetic repression of miR-29 by MYC, HDAC3, and EZH2 in mantle cell lymphoma and other MYC-associated lymphomas. We demonstrate that miR-29 is repressed by MYC through a corepressor complex with HDAC3 and EZH2. MYC contributes to EZH2 upregulation via repression of the EZH2 t...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2012.09.003

    authors： Zhang X,Zhao X,Fiskus W,Lin J,Lwin T,Rao R,Zhang Y,Chan JC,Fu K,Marquez VE,Chen-Kiang S,Moscinski LC,Seto E,Dalton WS,Wright KL,Sotomayor E,Bhalla K,Tao J

    更新日期：2012-10-16 00:00:00

  • Dysfunction of the Reciprocal Feedback Loop between GATA3- and ZEB2-Nucleated Repression Programs Contributes to Breast Cancer Metastasis.

    abstract：:How loss-of-function of GATA3 contributes to the development of breast cancer is poorly understood. Here, we report that GATA3 nucleates a transcription repression program composed of G9A and MTA3-, but not MTA1- or MTA2-, constituted NuRD complex. Genome-wide analysis of the GATA3/G9A/NuRD(MTA3) targets identified a ...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2015.04.011

    authors： Si W,Huang W,Zheng Y,Yang Y,Liu X,Shan L,Zhou X,Wang Y,Su D,Gao J,Yan R,Han X,Li W,He L,Shi L,Xuan C,Liang J,Sun L,Wang Y,Shang Y

    更新日期：2015-06-08 00:00:00

  • Defining the Molecular Alterations of Ampullary Carcinoma.

    abstract：:Ampullary carcinomas represent a group of heterogeneous tumors that can be histologically divided into two subtypes with distinct pathogenic and clinical characteristics. Yachida et al. (2016) and Gingras et al. (2016) now report the genomic landscape of ampullary carcinoma, providing insights into molecular drivers w...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2016.01.011

    authors： Tan J,Tan P,Teh BT

    更新日期：2016-02-08 00:00:00

  • Chromosomal instability in mouse metastatic pancreatic cancer--it's Kras and Tp53 after all.

    abstract：:A human pancreatic cancer progression model from intraepithelial neoplasia to ductal adenocarcinoma has been proposed. This process has been modeled in the mouse by activation of mutant Kras in pancreatic progenitor cells. In this issue of Cancer Cell, present a modification of their initial model by introducing a mut...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2005.04.025

    authors： Siveke JT,Schmid RM

    更新日期：2005-05-01 00:00:00

  • Directed phenotype switching as an effective antimelanoma strategy.

    abstract：:Therapeutic resistance in melanoma and other cancers arises via irreversible genetic, and dynamic phenotypic, heterogeneity. Here, we use directed phenotype switching in melanoma to sensitize melanoma cells to lineage-specific therapy. We show that methotrexate (MTX) induces microphthalmia-associated transcription fac...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2013.05.009

    authors： Sáez-Ayala M,Montenegro MF,Sánchez-Del-Campo L,Fernández-Pérez MP,Chazarra S,Freter R,Middleton M,Piñero-Madrona A,Cabezas-Herrera J,Goding CR,Rodríguez-López JN

    更新日期：2013-07-08 00:00:00

  • Next-generation genomic profiling of hepatocellular adenomas: a new era of individualized patient care.

    abstract：:Hepatocellular adenomas (HCAs) are clinically relevant benign liver lesions that commonly occur in women on hormonal contraceptives. In this issue of Cancer Cell, Pilati and colleagues present an integrative multi-"omics"-based analysis of HCA and identify recurrent genetic alterations associated with adenoma-carcinom...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2014.03.032

    authors： Marquardt JU,Thorgeirsson SS

    更新日期：2014-04-14 00:00:00

  • Does CSF1R Blockade Turn into Friendly Fire?

    abstract：:In this issue of Cancer Cell, Kumar et al. describe how CSF1R blockade induces not only an expected deprivation of tumor-associated macrophages, but also an accumulation of tumor-infiltrating polymorphonuclear mononuclear cells caused by Cxcl-1 released from cancer-associated fibroblasts. ...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2017.10.012

    authors： Greten TF

    更新日期：2017-11-13 00:00:00

  • New Views into the Genetic Landscape of Metastatic Breast Cancer.

    abstract：:Whether metastasis-specific genetic alterations exist remains controversial. The study by Yates et al. in this issue of Cancer Cell provides evidence that metastases emerge late during primary breast cancer progression and that additional driver mutations are often acquired, posing both challenges and opportunities fo...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2017.07.011

    authors： Zhao X,Powers S

    更新日期：2017-08-14 00:00:00

  • Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy.

    abstract：:To identify regulatory drivers of prostate cancer malignancy, we have assembled genome-wide regulatory networks (interactomes) for human and mouse prostate cancer from expression profiles of human tumors and of genetically engineered mouse models, respectively. Cross-species computational analysis of these interactome...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2014.03.017

    authors： Aytes A,Mitrofanova A,Lefebvre C,Alvarez MJ,Castillo-Martin M,Zheng T,Eastham JA,Gopalan A,Pienta KJ,Shen MM,Califano A,Abate-Shen C

    更新日期：2014-05-12 00:00:00

  • Adipocyte p62/SQSTM1 Suppresses Tumorigenesis through Opposite Regulations of Metabolism in Adipose Tissue and Tumor.

    abstract：:Obesity is a leading risk factor for cancer. However, understanding the crosstalk between adipocytes and tumor cells in vivo, independently of dietary contributions, is a major gap in the field. Here we used a prostate cancer (PCa) mouse model in which the signaling adaptor p62/Sqstm1 is selectively inactivated in adi...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2018.03.001

    authors： Huang J,Duran A,Reina-Campos M,Valencia T,Castilla EA,Müller TD,Tschöp MH,Moscat J,Diaz-Meco MT

    更新日期：2018-04-09 00:00:00

  • Cancer therapeutics in yeast.

    abstract：:The budding yeast Saccharomyces cerevisiae is a genetically tractable model system with which to establish the cellular target of a given agent and investigate mechanisms of drug action. ...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/s1535-6108(02)00160-5

    authors： Bjornsti MA

    更新日期：2002-10-01 00:00:00